Professor, Medicine, OR Hlth Sci Univ Sch of Med
Oncology
Dr. Charles D. Blanke, MD
|
|
Give Review
Charles Blanke works in the field of Oncology. He studied medicine at Indiana University School of Medicine. Indiana University School of Medicine is ranked 45/47 in Research/PrimaryCare. He over the years received 1 awards: "Whos Who in Medicine and Healthcare". Charles D. Blanke is also a published doctor. He has 68 paper published. The most recent paper is: Next steps for adolescent and young adult oncology workshop: An update on progress and recommendations for the future. Doctor Charles D. Blanke, MD accepts Medicare.
Publications
- Next steps for adolescent and young adult oncology workshop: An update on progress and recommendations for the future.
- S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors.
- Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.
- Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.
- Age-Related Cataract in Men in the Selenium and Vitamin E Cancer Prevention Trial Eye Endpoints Study: A Randomized Clinical Trial.
- Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic Cancer: Phase Ib and randomized phase II...
- Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial.
- S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.
- Higher capecitabine AUC in elderly patients with advanced coloRectal cancer (SWOGS0030).
- Assessment of HER2 gene amplification in adenocarcinomas of the Stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.
- Comparison of Dietary and Lifestyle Habits Among Stage III and Metastatic ColoRectal Cancer Patients: Findings from CALGB 89803 and CALGB 80405.
- Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon Cancer: findings from the Adjuvant Colon Cancer Endpoints data set.
- Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Re...
- S0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophag...
- ColoRectal Chemoprevention Pilot Study (SWOG-9041), randomized and placebo controlled: the importance of multiple luminal lesions.
- SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.
- Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials.
- Survival for Metastatic Colorectal Cancer in the Bevacizumab Era: A Population-based Analysis.
- A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder Cancer or cholangiocarcinoma: Southwest Oncology Group study S...
- Commentary: clinical trials represent the best Cancer care. Or do they?
- Gastrointestinal stromal tumors: disease and treatment update.
- Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415).
- Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced Pancreatic adenocarcinoma: Southwest Oncology Group-directed intergro...
- Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemci...
- S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the Stomach.
- Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon c...
- Phase II trial of romidepsin (NSC-630176) in previously treated coloRectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336).
- Biomarkers in GIST: partly ready for prime-time use.
- Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor.
- Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.
- Successes and challenges in translational research: the development of targeted therapy for gastrointestinal stromal tumours.
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
- Dual-antibody therapy in advanced coloRectal cancer: gather ye rosebuds while ye may.
- Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early resul...
- Perioperative treatment of gastrointestinal stromal tumors.
- Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal st...
- Postchemotherapy hyperammonemic encephalopathy emulating ornithine transcarbamoylase (OTC) deficiency.
- Perforation and Stage-II Colon Cancer: Is it Always High Risk?
- Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stro...
- Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expre...
- Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated adva...
- Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal Cancer.
- The continuum of care: a paradigm for the management of metastatic coloRectal cancer.
- Gastrointestinal stromal tumors: imatinib and beyond.
- Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.
- Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
- Outcome following surgical therapy for gastrointestinal stromal tumors.
- Impact of the year 2000 Medicare policy change on older patient enrollment to Cancer clinical trials.
- Management of gastrointestinal stromal tumors in the imatinib era: selected case studies.
- Disease-free survival versus overall survival as a primary end point for adjuvant colon Cancer studies: individual patient data from 20,898 patients on 18 randomized t...
- Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced coloRectal adeno...
- Gefitinib in coloRectal cancer: if wishes were horses.
- Whither irinotecan?
- Gastrointestinal stromal tumors and the evolution of targeted therapy.
- Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal Cancer.
- Cyclooxygenase-2 inhibition in coloRectal cancer: boom or bust?
- A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable coloRectal cancer.
- State-of-the art therapy for gastrointestinal stromal tumors.
- Targeted therapies in the treatment of coloRectal cancer: what managed care needs to know.
- Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib.
- Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
- Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia.
- Pulmonary and intracerebral plasmacytomas in a patient without multiple myeloma: a case report.
- Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
- Cancers of the gallbladder and biliary ducts.
- Celecoxib with chemotherapy in coloRectal cancer.
- Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive Malignancies.
Schools
Northwestern Center Feinberg School of Medicine
Lacrosse Luth Hospital
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- ColoRectal Cancer
- Liver Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Whos Who in Medicine and Healthcare
Education
-
Indiana University School of Medicine -
Northwestern University Feinberg School of Medicine
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1639187198 |
| Last Name Of The Provider | BLANKE |
| First Name Of The Provider | CHARLES |
| View All |
Similar Doctors
|
Dr. Kathryn R. Shell, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Prashant Shankar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Keith S. Lanier, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jacqueline Vuky, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lara E. Davis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Walter J. Urba, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rui Li, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brandon M. Hayes-Lattin, MD
This Doctor is OpenDoctor Recommended.
|